Guest guest Posted May 3, 2001 Report Share Posted May 3, 2001 Lichen sclerosis: early diagnosis is the key to treatment. ------------------------------------------------------------------------------ -- ------------------------------------------------------------------------------ -- Vulvar lichen sclerosus (VLS) is a serious chronic dermatologic and gynecologic condition associated with epithelial thinning, inflammation, and distinctive dermal changes. The most prevalent symptom is the intense pruritus of the vulvar area. This disease is most common in postmenopausal women but is recently being diagnosed more frequently in premenopausal women. Once thought to be a rare condition, VLS is now one of the most common conditions seen in vulvar clinics. The prevalence of VLS remains unknown. The disease is frequently misdiagnosed as chronic vaginitis. The misdiagnosis of chronic vaginitis is easily attributed to the similarity of symptoms. During the early stages of the disease, misdiagnosis is common because there are no apparent skin changes [1,2] If vulvar lichen sclerosus is left untreated there is a loss of normal vulvar structure. As the disease progresses there is a loss of distinction between the labia majora and minora, along with the loss of the clitoral hood. Eventually the clitoris will be covered by the fusing labia. The perineal area shrinks, which may preclude intercourse or result in painful intercourse. When there is splitting of the involved skin between the vagina and rectum this may cause painful defecation with bleeding. Excoriation of the area occurs due to the intense pruritus [2]. While lichen sclerosus is found in both males and females and in all age-groups [1,2], this article focuses on lichen sclerosus in females in the vulvar area. The few articles published on this condition focus primarily on the disease at the cellular level or on other aspects of VLS not addressed in this article [3-8]. Epidemiology Lichen sclerosus (LS) is found in all age groups, both male and female. The onset of the disease may occur between 6 months of age and late adulthood. Lichen sclerosus may appear anywhere on the body. Extrogenital sites include the neck, shoulders, and back, and are generally asymptomatic. The most common site in females is the vulvar and surrounding areas. Most patients are described as Caucasian, but lichen sclerosus has been found in African, Asian, and other dark-skinned patients. Women are diagnosed more frequently with LS than men [2,7,8]. In uncircumcised males, LS has been reported on the prepuce. Most consider trauma or chronic infection as the cause. Circumcision is the treatment of choice. Ridley suggests that early circumcision may protect males against LS. Incidences of malignancy have been reported in males [8,9]. In children, LS is more common than is currently recognized; LS affects children from age 6 months to late adolescence. Often there is a delay in treatment due to the inexperience of the clinician and the misdiagnosis of sexual abuse. This is not to say that sexual abuse and VLS do not coexist but that the trauma to the area mimics the abuse and makes diagnosis difficult [8-10]. One problem in reporting the incidence of VLS in children or adult females is the interchangeable terms of " genital " versus " vulva " and " perineal " versus " groin. " Some congruity is needed in the description of involved areas [8]. Clinical Manifestations Most female patients with VLS seek health care with complaints of severe vulvar pruritus and are in their perimenopausal or postmenopausal years. Other symptoms include burning pain, dyspareunia, dysuria, vaginal discharge, and anal or genital bleeding along with labial stenosis or fusion. This is where the misdiagnosis of vaginitis is often made [2,8]. With vaginitis (candidiasis or yeast infection), the patient complains of severe itching, burning, and irritation in the vulvar region. A complaint of discharge and discomfort during intercourse is also made. The labia majora is swollen and excoriated. With bacterial vaginitis, the complaint is of a foul-smelling discharge, irritation, and severe itching. With the symptoms being similar in vaginitis and VLS, it is easily understood why some misdiagnoses can occur [11]. If the patient continues to complain about pruritus, and vaginitis has been ruled out, the clinician may want to consider VLS. The distinct tissue changes are often the first visual indication of VLS, but only a biopsy can confirm the diagnosis and rule out a malignancy [2]. Vulvar lichen sclerosus is not considered to be a premalignant condition, although areas of hyperplastic epithelium changes from lichen sclerosus can be sites of premalignant or malignant changes [2,12]. However, an increased risk does exist. The reported incidence of squamous cell carcinoma (SCC) ranges between 6% and 25% in women with VLS. In a more recent study of 78 cases of the carcinoma, LS was found in 61% of the women. In these women, squamous cell carcinomas were confined to the labia minora and clitoris [9,13]. In a review of LS cases of 4,280 females and 691 males, genital LS was the highest at 4,308. Squamous cell carcinoma was 283 with 291 having an autoimmune disease and another 316 having the auto-antibodies. The neck, shoulders, and upper trunk were the most common nongenital sites reported in 805 cases [8]. The incidence of approximately 6% with genital cancer is a relatively high incidence given the rarity of vulvar carcinoma. In a 1995 study, it was found that of the 211 female subjects that had histologically demonstrated VLS, three developed SCC. This study showed that the chance of developing SCC in women with VLS is more than 300-fold higher than that of women without VLS in the same age group [14]. The intense pruritus causes the patient to scratch, which results in excoriation of the skin. This intense itch-scratch-itch cycle can seriously affect one's quality of life. Scratching causes erosions to occur which cause burning on urination. This symptom can confuse the clinician causing repeated unnecessary urine testing all with negative results. According to some researchers, because of this repeated trauma the areas of VLS may become hyperplastic. These areas of hyperplastic epithelium are believed to be at risk for SCC [2,12,13]. Pathogenesis The exact pathogenesis of VLS is not clear, but there are many old theories concerning the cause of lichen sclerosus. In 1903, the cause was first described as a local interference with the blood supply to the vulvar area. Little was written about LS until a 1952 report suggesting that women who were " hysterical, " " excitable, " or " highly nervous " were at a greater risk of developing VLS [8]. Two main theories exist concerning the cause of VLS. One current theory is that VLS is caused by an infectious disease or a virus. Borrelia burgdorferi, the causative agent in Lyme disease, was speculated to be the cause of VLS. Even though some studies showed evidence of a Borrelia infection, the results were conflicting and inconclusive. It was also once believed that VLS was another manifestation of syphilis. Some patients with VLS have been diagnosed with syphilis, but a new spirochete has become a suspect in VLS. Researchers have found these spirochetes in the papillary dermis of 48% of patients with VLS, especially in early cases [8,12]. The second theory involves the interaction of hormones, fibroblasts, and changes in collagen. This theory has been studied for decades without any universal agreement on the pathogenesis of VLS. Hormonal studies focus on the actions of testosterone. Patients with VLS were found to have a decreased serum level of free testosterone, androstenedione, and dihydrotestosterone. A defect in the function of 5 [Alpha]-reductase, an enzyme that shows increased activity in genital skin when compared to nongenital skin, is believed to be the underlying defect predisposing these patients to VLS [7-9]. Other theories conclude that LS could be caused by the isomorphic or " Koebner " phenomenon. This theory includes the premise that friction caused by tight clothing may cause and spread LS. Some theorize that the trauma of skin rubbing against skin is the trigger for genital and extragenital LS. Early dermatologic literature states that LS occurring on the back and shoulders is caused from brassiere straps. Also included in this theory is that trauma, repeated masturbation, " garden variety " local flora, mycobacteria or pneumococcus, the warm and moist area, or a low-grade infection all play a role in the development of VLS [8]. There are also other theories relating to various mechanisms that could affect VLS. These theories include immunologic, genetic, androgen receptor inactivity or deficiency, and peridermal growth factor deficiency [2,7,8]; Genetic studies remain inconclusive. VLS has been reported in families, but no consistent autosomal or X-linked genetic pattern has been found [8]. Since 1910, attempts have been made to link LS to autoimmune disorders. The most common diseases linked to LS are thyroid disease (Graves' disease) and type I and type II diabetes. A thyroid test is recommended in patients with LS. In both sexes, vitiligo and alopecia areata have been reported with genital and extragenital LS. Other immune-related conditions that are associated with LS include: achlorhydria with and without pernicious anemia, lichen planus, atopic dermatitis, eczema, psoriasis, polymyalgia rheumatica, fascitis, primary biliary cirrhosis, myositis, lupus panniculitis, and systemic lupus erythematosus [8]. One study suggested that nonsmokers were more likely to have VLS than smokers. The androgen-elevating effect of cigarette smoking is thought to be the cause of lower incidence of VLS in smokers [8]. Diagnosis The vulvar area should be carefully observed in all patients with a complaint of severe pruritus of the vaginal area (and particularly when a vaginal infection has been ruled out). A patient with VLS will have thin, white skin, localized to the labia minora/majora (Figures 1 and 2). The vulvar area will also have white papules with an erythematous halo and keratotic plugging [8]. [Figure 1 and 2 ILLUSTRATION OMITTED] Initially, VLS begins as white polygonal papules that form into plaques with fine crinkling. These hypopigmented areas are generally seen peripherally in the perineum, perianally, or on the external aspect of the labia majora. There may also be a pattern of a waxy appearance of the labia minora with speckling. As VLS progresses the fragility of the skin becomes evident by tears in the skin along with the appearance of purpura. The area is easily excoriated due to the constant rubbing and scratching [8,9,13]. It cannot be stressed enough that clinicians must perform a meticulous search for VLS and other lesions especially in women with a chief complaint of vulvar pruritus or labial dysuria during a pelvic exam. If diagnosed early, proper treatment can be started along with appropriate follow-up care [2,8,9,12,13]. The accuracy of a biopsy in diagnosing VLS is debatable. If the symptoms are minimal and the skin changes are questionable, then a biopsy should be performed to confirm VLS. Only a biopsy can rule out SCC. However, there is a drawback to the biopsy. Sometimes in patients with subtle clinical signs, the results of the biopsy may be difficult to interpret and a definite diagnosis of VLS may be impossible [9,13]. If the disease is suspected, a biopsy may confirm the diagnosis and determine if it is malignant [2]. There are other differential diagnoses that the clinician should consider with a complaint of vulvar pruritus. Some dermatologic conditions that should be considered are eczema, lichen simplex, and psoriasis. Neoplasia conditions include SCC, vulvar intrepithelial neoplasia, and other malignancies. Also with infection, the clinician should consider vaginal warts as a possible diagnosis [3]. Treatment Treatment begins with an effort to control the pruritus. This can be accomplished by prescribing a medium potency steroid ointment such as betamethasone valerate 0.1% (Beta-Val, Betatrex, Valisone, Canadian: Beben, Betaderm, Betnesol, Celestone, Diprolent, and Diprosone). Creams are not as effective in controlling the pruritus as ointments. The patient must apply the ointment to the affected area 2 to 3 times daily for 2 weeks. The clinician needs to understand that prolonged use of medium- or high-potency steroids may cause thinning of vulvar skin outside the field of lichen sclerosus. Superpotent steroids such as halobetasol (Ultravate) and clobetasol (Temovate) may be used for short periods, after biopsies have ruled out neoplastic changes. If the area becomes unresponsive to the topical ointments, it may be necessary to inject intralesional steroids such as triamcinolone acetonide (aristocort, azmacort, kenalog-10, Canadian: aristocort, azmacort, kenalog, and triaderm) directly into the area [2]. Some concerns are associated with the use of super-potent topical steroids. The steroids can relieve some symptoms in VLS especially pruritus. There have been concerns that use of the steroids could lead to local infections but no evidence suggests this. The steroids may cause skin thinning which is also a symptom of VLS. Contact sensitivity to the steroids has been well documented and must be considered prior to patient use [15]. The most common form of treatment is 2% testosterone proprionate in petrolatum. This ointment is applied 2 to 3 times per day for up to 6 months. After the initial treatment the testosterone is decreased to only once per day; this is based on the patient's response to treatment and any side effects. The patient needs to know that this is a lifelong treatment. The side effects from the testosterone can cause clitoromegaly, hirsutism, and the development of male characteristics [2,16]. Topical testosterone provides the best results improving gross and histopathologic changes in the tissue. In one study conducted on 30 subjects with VLS using testosterone, after 1 year of therapy 20 patients (66.6%) in the testosterone group had considerable improvement, six patients (20%) were unchanged, and four (13.4%) became worse. The pruritus was the most improved symptom [4]. The use of topical progesterone has also been effective in the treatment of VLS. The dose is 200 mg of progesterone in oil mixed with two ounces of hydrophilic ointment. The success rate was only 50%. The use of topical cyclosporine has shown some promise in patients with VLS. The dose is 200 mg/day of cyclosporine with the usual dosage of 50 mg four times/day for 8 weeks. Only three patients were evaluated in this study [12]. Some patients may benefit from sedation at night during the early phase of the disease to help with the pruritus. Low doses of tricyclic antidepressants help patients who are anxious or tearful. This will help the patient to rest at night [13]. In patients that have SCC, it will be necessary to remove the affected areas. This involves major surgery and affects the patient's body image. At one time a vulvectomy was the primary treatment for VLS; however there was a high incidence of recurrence of VLS after the excision. In some cases skin grafting was attempted but VLS recurred in the grafted skin. Unless there is a malignancy a vulvectomy is contraindicated [8,9,12]. The patient needs to have regular visits to her clinician every 3 months to check the progression of VLS. This is very important in the early detection of cancer. Patients with hyperplastic lesions should be seen more frequently. Conclusion Vulvar lichen sclerosus is frequently misdiagnosed by many clinicians. The clinician needs to devote more care when performing a pelvic exam so that VLS can be detected in the early stages when treatment is most helpful. This article summarizes the diagnosis and treatment of VLS to help clinicians understand and meet the needs of the patient with VLS in order to detect this disease during its early stages. REFERENCES [1.] Dalziel KL: Effect of liche Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.